Innate Pharma’s Post

Regeneron Pharmaceuticals revealed promising findings from the Phase I/II LINKER-MM1 trial of linvoseltamab in patients suffering with relapsed/refractory multiple myeloma during the oral plenary session at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego. Linvoseltamab, an investigational bispecific antibody, demonstrates its potential by bridging B-cell maturation antigen (BCMA) on multiple myeloma cells with CD3-expressing T cells, thereby triggering T-cell activation and subsequent cancer-cell elimination. For more detailed analysis, read: https://lnkd.in/gGQGbQZX #multiplemyeloma #linvoseltamab #relapsedrefractorymultiplemyeloma #clincialtrials #cancer #cancercells

Latest Healthcare News & Updates: Bayer Starts Phase III Trial In Non-Small Cell Lung Cancer (NSCLC) D&D Pharmatech Secures FDA Approval for Phase II Trial of GLP-1R Agonist in Multiple Sclerosis MSD Halts Two KEYTRUDA Phase III Cancer Trials Following Unfavorable Results Novartis Plots LEQVIO Expansion After Lowering Cholesterol in Phase III Study Alnylam Pharmaceuticals Builds ATTR-CM Case for Vutrisiran With Strong Phase III Survival Data Get more detailed analysis, at: https://lnkd.in/gc3U4nqj #lifesciences #pharmaceuticals #marketresearch #marketanalysis #healthcare #markettrends #health #medical #news #healthcarenews #pharmanews #clinicaltrials #clinicalresearch

🥇Check out the Editor's Choice #Review "The Implementation of TNFRSF Co-Stimulatory Domains in CAR-T Cells for Optimal Functional Activity" 🧐by Yuan He, Martijn Vlaming et al. China Pharmaceutical University, University of Groningen 🔗Link here: https://lnkd.in/dWpVFQgX ✨This review discusses the significance of the Tumor Necrosis Factor Receptor Superfamily (TNFRSF) in providing co-stimulatory signals to immune effector cells and how these signals can be utilized in tailoring Chimeric Antigen Receptor (CAR) T cell activity for cancer therapy. It highlights specific TNFRSF members that have gained prominence as co-stimulatory domains in CAR-T cell therapy, emphasizing their unique attributes and potential applications in enhancing CAR-T cell function✨

Does the future of head and neck squamous cell carcinoma (HNSCC) run through Merus N.V.’ petosemtamab? We will be speaking with a leading #oncologist to find out. Learn more here: https://lnkd.in/dFrw4Ejj #biotechnology #cancer #clinicalresearch #medicalaffairs #Merus #pharmaceuticals

Things are heating up in the PD-L1xVEGF bispecific antibody space after Summit Therapeutics, Inc. revealed phase 3 clinical trial data for ivonescimab last week. BioNTech SE released phase 2 clinical trial data for BNT327 showing its efficacy is on par with ivonescimab, and less anti-VEGF-related toxicity compared to bevacizumab. Instil Bio plans to license ImmuneOnco's IMM2510. Summit's phase 3 data showed 29% of patients experience adverse effects severe enough to require medical intervention, where that only occurs in 16% of Keytruda patients. In the phase 2 clinical trial, 31% of BNT327 patients experience adverse effects that disrupted dosing. Time will tell whether the benefits outweigh the risks. https://lnkd.in/g37mbqQh With this flurry of activity, contenders could be coming for Keytruda's crown soon. I'm excited to see what sort of patient outcomes we'll see in the future

Just over a week after scrapping development of magrolimab in haematologic #cancers, Gilead Sciences is now pausing work on the anti-CD47 antibody in solid tumours as well. https://lnkd.in/dE4x595f #biotechnology #clinicalresearch #clinicaltrials #drugdevelopment #FDA #Gilead #oncology #pharmaceuticals #regulatoryaffairs

Prostate Cancer Combination Treatment TALZENNA® and XTANDI® Receives European Commission Approval Pfizer has received approval from the European Commission for the use of TALZENNA (talazoparib) in combination with XTANDI (enzalutamide) for the treatment of metastatic castration-resistant prostate cancer. This is the first approval of a PARP inhibitor in combination with XTANDI for this type of prostate cancer in the European Union. The approval is based on data from the Phase 3 TALAPRO-2 trial, which showed that the combination therapy reduced the risk of disease progression or death compared to placebo. This approval provides a new treatment option and brings hope to patients with this aggressive form of prostate cancer. For more details please click the link! https://lnkd.in/d8RXn4PV #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐑𝐞𝐬𝐮𝐥𝐭𝐬 𝐟𝐫𝐨𝐦 𝐓𝐑𝐎𝐏𝐈𝐎𝐍-𝐋𝐮𝐧𝐠𝟎𝟏 𝐏𝐡𝐚𝐬𝐞 𝐈𝐈𝐈 𝐓𝐫𝐢𝐚𝐥 Datopotamab deruxtecan (Dato-DXd) demonstrates promising results in locally advanced or metastatic non-small cell lung cancer (NSCLC). In the overall trial population, Dato-DXd numerically favors OS compared to docetaxel, with statistically significant improvement in PFS, especially in nonsquamous NSCLC. Safety profile of Dato-DXd is consistent with fewer adverse events compared to docetaxel, with no new safety concerns identified. Susan Galbraith, EVP Oncology R&D, AstraZeneca, and Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo, express optimism about Dato-DXd potentially replacing conventional chemotherapy in late-line setting. Dato-DXd, a TROP2-directed DXd antibody drug conjugate, is jointly developed by AstraZeneca AstraZeneca and Daiichi Sankyo Daiichi Sankyo. These promising findings will support regulatory applications globally for adult patients with locally advanced or metastatic nonsquamous NSCLC who received prior systemic therapy. #LungCancerResearch #NSCLCtreatment #ClinicalTrialResults #DatoDXd #CancerTreatment #OncologyNews #MedicalBreakthrough #AstraZeneca #DaiichiSankyo

[Clinical Trials] ImmunityBio, Inc.'s phase 2/3 trial of Anktiva assesses CR incidence and survival in bladder cancer https://lnkd.in/gSfDi5uP Johnson & Johnson's phase 3 trial of nipocalimab reaches primary endpoints in gMG and SjD studies https://lnkd.in/gmtEQksG Vertex Pharmaceuticals' phase 3 trials of Vanza Triple meets primary endpoint matches TRIKAFTA in cystic fibrosis lung function improvement https://lnkd.in/geZbXqfV Sangamo Therapeutics, Inc. Therapeutics' phase 1/2 trial of ST-920 exhibits sustained α-Gal A activity in Fabry disease https://lnkd.in/gtAjZjEZ GSK's phase 3 trial of Blenrep in multiple myeloma indicates extended progression-free survival over daratumumab combination https://lnkd.in/gbgkYXGn [Deals] Novartis Signs Agreement to Acquire MorphoSys for EUR 2.7 Billion Securing Ownership of phase 3 BET Protein Inhibitor Pelabresib and Tulmimetostat https://lnkd.in/gPYc2DE8

According to the CDE (Center for Drug Evaluation) website, Johnson & Johnson (China) Investment Ltd. (hereinafter referred to as "Johnson & Johnson") has received implicit approval for clinical trials of its Class 1 chemical drug JNJ-88998377 oral tablets. The indicated conditions for this drug include B-cell non-Hodgkin lymphoma (diffuse large B-cell lymphoma [DLBCL], mantle cell lymphoma [MCL], mucosa-associated lymphoid tissue lymphoma [MALT lymphoma], follicular lymphoma [FL], and Waldenström's macroglobulinemia [WM]). #APIs #Medical #Rawmaterials #Pharma #Medicine #Pharmaceutical